Notice: This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GXGX vs. NLTX, ENTA, SCPH, ACRV, RENB, IVA, ADCT, GLSI, NKTR, and NVCTShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), scPharmaceuticals (SCPH), Acrivon Therapeutics (ACRV), Renovaro (RENB), Inventiva (IVA), ADC Therapeutics (ADCT), Greenwich LifeSciences (GLSI), Nektar Therapeutics (NKTR), and Nuvectis Pharma (NVCT). These companies are all part of the "medical" sector. GX Acquisition vs. Neoleukin Therapeutics Enanta Pharmaceuticals scPharmaceuticals Acrivon Therapeutics Renovaro Inventiva ADC Therapeutics Greenwich LifeSciences Nektar Therapeutics Nuvectis Pharma GX Acquisition (NASDAQ:GXGX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Does the media favor GXGX or NLTX? In the previous week, GX Acquisition's average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score. Company Overall Sentiment GX Acquisition Neutral Neoleukin Therapeutics Neutral Do institutionals and insiders believe in GXGX or NLTX? 61.7% of GX Acquisition shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, GXGX or NLTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGX AcquisitionN/AN/A-$49.26MN/AN/ANeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.48 Is GXGX or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets GX AcquisitionN/A -985.20% -6.02% Neoleukin Therapeutics N/A -37.22%-30.91% Which has more volatility and risk, GXGX or NLTX? GX Acquisition has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Does the MarketBeat Community believe in GXGX or NLTX? Neoleukin Therapeutics received 48 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformGX AcquisitionOutperform Votes2100.00% Underperform VotesNo VotesNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% SummaryGX Acquisition and Neoleukin Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Remove Ads Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.16M$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E RatioN/A6.1223.7319.00Price / SalesN/A226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book9.576.656.904.26Net Income-$49.26M$139.34M$3.18B$247.00M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$1.34+2.3%N/A-81.2%$48.16MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$17.69+3.5%N/A-53.2%$166.25MN/A-5.6990ENTAEnanta Pharmaceuticals4.4507 of 5 stars$7.33-5.8%$17.25+135.3%-52.1%$165.97M$66.59M-1.48160Short Interest ↓Positive NewsSCPHscPharmaceuticals3.6221 of 5 stars$3.21-2.1%$15.00+367.3%-41.7%$164.13M$30.28M-1.6930ACRVAcrivon Therapeutics2.8017 of 5 stars$5.14-3.2%$23.67+360.4%+10.1%$160.04MN/A-1.9058Short Interest ↓News CoveragePositive NewsGap UpRENBRenovaro1.3833 of 5 stars$0.89-9.0%N/A-70.8%$155.96MN/A-0.9620IVAInventiva2.0131 of 5 stars$2.96-6.6%$12.60+325.7%-22.9%$155.33M$15.62M0.00100Positive NewsADCTADC Therapeutics1.5373 of 5 stars$1.60-9.4%$8.50+432.9%-61.0%$154.22M$70.72M-0.67310GLSIGreenwich LifeSciences2.1843 of 5 stars$11.70-4.3%$38.00+224.8%-34.0%$153.80MN/A-14.623NKTRNektar Therapeutics4.3786 of 5 stars$0.80-4.5%$4.08+409.2%-1.5%$147.92M$93.14M-0.95220Earnings ReportUpcoming EarningsGap UpNVCTNuvectis Pharma3.1374 of 5 stars$6.14-8.2%$11.00+79.2%-27.8%$143.63MN/A-5.298Short Interest ↓ Remove Ads Related Companies and Tools Related Companies NLTX Competitors ENTA Competitors SCPH Competitors ACRV Competitors RENB Competitors IVA Competitors ADCT Competitors GLSI Competitors NKTR Competitors NVCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GXGX) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersTrump announces revenge on BidenA former CIA insider just made a stunning prediction: Trump’s revenge on Biden will end America’s energy cr...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
